All In Biotech

Drug Trial Radar · NCT01453855

Travoprost 3-Month Safety and Efficacy Study

A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Oct 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,099 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,099

Actual

Start

Nov 2011

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Oct 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Travoprost ophthalmic solution, 0.003%Drug

  • Travoprost ophthalmic solution, 0.004%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)Time frame: Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.